Daigen Xu

Summary

Affiliation: F. Hoffmann-La Roche Ltd

Publications

  1. Xu D, Kim Y, Postelnek J, Vu M, Hu D, Liao C, et al. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J Pharmacol Exp Ther. 2012;341:90-103 pubmed publisher
  2. Liao C, Hsu J, Kim Y, Hu D, Xu D, Zhang J, et al. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy. Arthritis Res Ther. 2013;15:R146 pubmed publisher
    ..RO9021 could serve as a starting point for the development of selective SYK inhibitors for the treatment of inflammation-related and autoimmune-related disorders. ..